Adaptive Biotechnologies Reports Strong Q1 2025 Growth

Adaptive Biotechnologies ( (ADPT) ) has released its Q1 earnings. Here is a breakdown of the information Adaptive Biotechnologies presented to its investors.

Adaptive Biotechnologies is a commercial-stage biotechnology company focused on translating the genetics of the adaptive immune system into clinical products for diagnosing and treating diseases, with a strong emphasis on cancer and autoimmune disorders.

In its first quarter of 2025, Adaptive Biotechnologies reported a robust financial performance, highlighted by a significant increase in revenue driven by the growth of its Minimal Residual Disease (MRD) business. The company also announced an upward revision of its full-year MRD revenue guidance while managing to lower its operating expenses and cash burn targets.

The company achieved a 25% increase in total revenue, reaching $52.4 million, with the MRD segment contributing 83% of this figure and experiencing a 34% growth compared to the previous year. The clonoSEQ test volume saw a 36% increase, and the company benefited from expanded Medicare coverage for clonoSEQ in mantle cell lymphoma. Additionally, Adaptive Biotechnologies recognized $4.5 million in MRD pharma regulatory milestone revenue.

Despite a net loss of $29.8 million, the company showed improvement from the previous year’s loss of $47.5 million. Operating expenses decreased by 9%, and the adjusted EBITDA loss narrowed significantly. The company’s cash position remained strong with $232.8 million in cash, cash equivalents, and marketable securities.

Looking ahead, Adaptive Biotechnologies is optimistic about its MRD business, expecting full-year revenue between $180 million and $190 million. The company is committed to driving its MRD segment towards profitability while advancing its Immune Medicine drug discovery programs to create long-term value for stakeholders.